Beam Therapeutics Reports Durable Phase 1/2 Safety and Efficacy in 29 Patients
BEAM•Beam Therapeutics presented additional Phase 1/2 single-dose data for BEAM-302 in 29 alpha-1 antitrypsin deficiency patients, highlighting detailed safety outcomes, durable efficacy and reduced neutrophil elastase activity. Based on FDA feedback, Beam plans to enroll ~50 more patients and initiate a pivotal cohort in H2 2026.
1. Conference Presentation of BEAM-302 Data
Beam Therapeutics presented updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the ATS 2026 conference in Orlando, showcasing additional single-dose cohort results beyond previously reported topline findings from 29 patients as of the February 10, 2026 cutoff.
2. Key Safety, Efficacy and Biomarker Findings
The data detailed comprehensive safety outcomes, durable restoration of alpha-1 antitrypsin function and measurable reduction in human neutrophil elastase activity, indicating that a single administration may correct the PiZ mutation and sustain therapeutic AAT levels over time.
3. Accelerated Approval Strategy and Pivotal Cohort Plans
Following FDA feedback, Beam intends to pursue an accelerated approval pathway for BEAM-302, enroll approximately 50 additional AATD patients and launch a pivotal Phase 1/2 cohort in the second half of 2026 to support a future biologics licensing application.
